Recent Finacing
Recent Raise
Simcha Therapeutics engineers cytokine variants via directed evolution, developing ST-067, an IL‑18 variant engineered to evade IL‑18BP and selectively activate IL‑18 receptor; Phase 1 initiated 2021.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Simcha Therapeutics.
